Ionis Pharmaceuticals Investigates Failure in Phase 3 Cardiac Trial
Ionis Pharmaceuticals disclosed its Phase 3 CARDIO-TTRansform trial missed its primary endpoint, causing shares to drop over 20%. An investigation into investor statements is underway.
Ionis Pharmaceuticals (NASDAQ: IONS) shares fell more than 20% on July 9, 2026, after the company revealed its Phase 3 CARDIO-TTRansform trial failed to meet its primary endpoint.
The investigation centers on whether the company's prior public statements about the CARDIO-TTRansform program were consistent with the trial's ultimate outcome. CEO Brett Monia had previously stated the trial was "on track" and "reasonably derisked for its primary endpoint."
Ionis announced that its trial, a collaboration with AstraZeneca, did not reduce combined cardiovascular death or recurrent events in patients with transthyretin-mediated amyloid cardiomyopathy. The stock's value declined sharply following this news.
Law firm Levi & Korsinsky is investigating potential securities law violations on behalf of Ionis Pharmaceuticals investors. They state that investors who purchased IONS stock and incurred losses are encouraged to contact the firm for further information.